Production (Stage)
Amylyx Pharmaceuticals, Inc.
AMLX
$5.31
-$0.05-0.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 204.07M | 176.50M | 234.40M | 309.81M | 373.29M |
| Total Receivables | 300.10K | 547.00K | 1.73M | 4.19M | 20.65M |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 11.78M | 12.38M | 9.14M | 12.72M | 16.59M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 216.14M | 189.43M | 245.26M | 326.72M | 410.53M |
|
|
|||||
| Total Current Assets | 216.14M | 189.43M | 245.26M | 326.72M | 410.53M |
| Net Property, Plant & Equipment | 2.07M | 2.73M | 3.53M | 4.24M | 5.71M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 1.46M | 1.47M | 1.92M | 1.20M | 1.21M |
| Total Assets | 219.68M | 193.63M | 250.71M | 332.16M | 417.46M |
|
|
|||||
| Total Accounts Payable | 4.81M | 2.94M | 1.49M | 4.96M | 21.45M |
| Total Accrued Expenses | 12.07M | 23.95M | 50.46M | 62.76M | 67.87M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 1.06M | 1.52M | 1.97M | 2.37M | 2.31M |
| Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Current Liabilities | -- | -- | -- | -- | -- |
| Total Current Liabilities | 17.93M | 28.41M | 53.92M | 70.08M | 91.64M |
|
|
|||||
| Total Current Liabilities | 17.93M | 28.41M | 53.92M | 70.08M | 91.64M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 327.00K | 463.00K | 595.00K | 772.00K | 1.38M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | -- | -- | -- | -- | -- |
| Total Liabilities | 18.26M | 28.87M | 54.51M | 70.85M | 93.02M |
|
|
|||||
| Common Stock & APIC | 844.02M | 771.55M | 764.71M | 757.85M | 748.26M |
| Retained Earnings | -642.60M | -606.69M | -569.15M | -496.44M | -423.74M |
| Treasury Stock & Other | -- | -92.00K | 641.00K | -97.00K | -77.00K |
| Total Common Equity | 201.42M | 164.77M | 196.20M | 261.31M | 324.44M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 201.42M | 164.77M | 196.20M | 261.31M | 324.44M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 201.42M | 164.77M | 196.20M | 261.31M | 324.44M |
|
|
|||||